Noticias de HIMS_US

Mercado

Noticias del mercado

Últimas noticias sobre HIMS_US — 694 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: HIMS_US 694 resultados
31/08/2026 HIMS_US — Yahoo Finance
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia

NEW YORK, Aug 31 (Reuters) - Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments ‌to men in Australia as it continues to expand its international business. Hims finalized ‌its acquisition of Australian digital health platform Eucalyptus, including its Sydney-based men

31/08/2026 HIMS_US — Pluang
FTC sues Hims & Hers over misleading charges an...

The Federal Trade Commission, along with California and Utah consumer protection agencies, sued Hims & Hers Health, Inc. for allegedly charging customers immediately after intake forms without clear disclosure and making subscription cancellations difficult. The FTC also claims the company misled consumers about privacy by sharing health data with third parties like Meta and Snap. Following the lawsuit announcement, Hims & Hers stock fell 14.73% to $25.00 per share. Investors and those affected are encouraged to contact Kaplan Fox & Kilsheimer LLP, which is investigating potential securities violations related to these allegations.

31/08/2026 HIMS_US — Future Market Insights
Enclomiphene Market

Enclomiphene Market worth USD 0.8 billion in 2026 is growing at a CAGR of 9.6% to reach USD 2.0 billion by 2036. Hims & Hers Health, Inc., Enhanced Group Inc., Mangoceuticals, Inc., BioScience Health Innovations, Inc., Maximus, SynergenX and West Bengal Chemical Industries Limited.

30/08/2026 HIMS_US — Stocktwits
HIMS Stock Posts Worst Day In A Month As Visa Flags Disputes — But Analyst Says GLP-1 Users Are Sticking Around

Hims faces an estimated $75,000 surcharge and must lower its dispute rate below 1.5%.

28/08/2026 HIMS_US — Yahoo Finance
Hims & Hers (HIMS) CEO Says the FTC Doesn’t Understand His Own Company

On August 18, 2026, Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum told CNBC that a Federal Trade Commission lawsuit over the company’s data-sharing and subscription practices “misunderstands how the company works.” He defended the company’s compounded GLP-1 drug sales as having helped lower prices for weight-loss treatments. Why This Matters Hims & Hers […]

28/08/2026 HIMS_US — Yahoo Finance
Hims & Hers (HIMS)’ Weight-Loss Plans Results Penalties Over Visa (V) Credit Card Disputes

On August 21, 2026, Bloomberg reported that Hims & Hers Health, Inc. (NYSE:HIMS) was enrolled in Visa Inc. (NYSE:V)’s Acquirer Monitoring Program after customer credit card disputes in its weight-loss subscription business exceeded acceptable levels in July. Each dispute carries an $8 surcharge, resulting in a bill of nearly $75,000 due in September, and Hims […]

28/08/2026 HIMS_US — HIMS investor relations
Investor relations
27/08/2026 HIMS_US — The National Law Review
Kaplan Fox is Investigating Potential Securities Law Violations Against Hims & Hers Health, Inc. (NYSE: HIMS)

NEW YORK, NY - August 27, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).

Página 5 de 35